Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...

Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.

Spain has begun using a new genetic ALS therapy that targets the SOD1 mutation and may slow nerve damage in patients with this rare condition.

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

Researchers at the University of Alabama at Birmingham are working to better understand ALS and find new ways to slow or stop the disease.

The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein can prevent neuron death caused by DNA damage and p53 activation in ...

ALS is a debilitating paralytic disease characterized by the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...